177 related articles for article (PubMed ID: 38345532)
1. Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
Sychev ZE; Day A; Bergom HE; Larson G; Ali A; Ludwig M; Boytim E; Coleman I; Corey E; Plymate SR; Nelson PS; Hwang JH; Drake JM
Mol Cancer Res; 2024 May; 22(5):452-464. PubMed ID: 38345532
[TBL] [Abstract][Full Text] [Related]
2. Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts.
Sychev ZE; Day A; Bergom HE; Larson G; Ali A; Ludwig M; Boytim E; Coleman I; Corey E; Plymate SR; Nelson PS; Hwang JH; Drake JM
bioRxiv; 2023 Aug; ():. PubMed ID: 37577653
[TBL] [Abstract][Full Text] [Related]
3. LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.
Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
[TBL] [Abstract][Full Text] [Related]
4. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
[TBL] [Abstract][Full Text] [Related]
5. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer.
Turnham DJ; Mullen MS; Bullock NP; Gilroy KL; Richards AE; Patel R; Quintela M; Meniel VS; Seaton G; Kynaston H; Clarkson RWE; Phesse TJ; Nelson PS; Haffner MC; Staffurth JN; Pearson HB
Cells; 2024 Apr; 13(8):. PubMed ID: 38667288
[TBL] [Abstract][Full Text] [Related]
6. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.
Labrecque MP; Brown LG; Coleman IM; Lakely B; Brady NJ; Lee JK; Nguyen HM; Li D; Hanratty B; Haffner MC; Rickman DS; True LD; Lin DW; Lam HM; Alumkal JJ; Corey E; Nelson PS; Morrissey C
Cancer Res; 2021 Sep; 81(18):4736-4750. PubMed ID: 34312180
[TBL] [Abstract][Full Text] [Related]
7. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
9. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.
Saraon P; Cretu D; Musrap N; Karagiannis GS; Batruch I; Drabovich AP; van der Kwast T; Mizokami A; Morrissey C; Jarvi K; Diamandis EP
Mol Cell Proteomics; 2013 Jun; 12(6):1589-601. PubMed ID: 23443136
[TBL] [Abstract][Full Text] [Related]
10. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
[TBL] [Abstract][Full Text] [Related]
11. Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo.
Zacharias N; Lee J; Ramachandran S; Shanmugavelandy S; McHenry J; Dutta P; Millward S; Gammon S; Efstathiou E; Troncoso P; Frigo DE; Piwnica-Worms D; Logothetis CJ; Maity SN; Titus MA; Bhattacharya P
Mol Imaging Biol; 2019 Feb; 21(1):86-94. PubMed ID: 29748904
[TBL] [Abstract][Full Text] [Related]
12. An original patient-derived xenograft of prostate cancer with cyst formation.
Yoshikawa T; Kobori G; Goto T; Akamatsu S; Terada N; Kobayashi T; Tanaka Y; Jung G; Kamba T; Ogawa O; Inoue T
Prostate; 2016 Aug; 76(11):994-1003. PubMed ID: 27098584
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
[TBL] [Abstract][Full Text] [Related]
14. Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Dalrymple S; Brennen WN; Isaacs JT; Li D; Lakely B; DeLucia DC; Lee JK; Schweizer MT; Lin DW; Corey E; Nelson PS; Morrissey C
Prostate; 2024 Jan; 84(1):100-110. PubMed ID: 37796107
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
[TBL] [Abstract][Full Text] [Related]
16. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
[TBL] [Abstract][Full Text] [Related]
17. Novel Dormancy Mechanism of Castration Resistance in Bone Metastatic Prostate Cancer Organoids.
Lee S; Mendoza TR; Burner DN; Muldong MT; Wu CCN; Arreola-Villanueva C; Zuniga A; Greenburg O; Zhu WY; Murtadha J; Koutouan E; Pineda N; Pham H; Kang SG; Kim HT; Pineda G; Lennon KM; Cacalano NA; Jamieson CHM; Kane CJ; Kulidjian AA; Gaasterland T; Jamieson CAM
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328625
[TBL] [Abstract][Full Text] [Related]
18. In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth.
Jiang N; Hjorth-Jensen K; Hekmat O; Iglesias-Gato D; Kruse T; Wang C; Wei W; Ke B; Yan B; Niu Y; Olsen JV; Flores-Morales A
Oncogene; 2015 May; 34(21):2764-76. PubMed ID: 25065596
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.
Labrecque MP; Coleman IM; Brown LG; True LD; Kollath L; Lakely B; Nguyen HM; Yang YC; da Costa RMG; Kaipainen A; Coleman R; Higano CS; Yu EY; Cheng HH; Mostaghel EA; Montgomery B; Schweizer MT; Hsieh AC; Lin DW; Corey E; Nelson PS; Morrissey C
J Clin Invest; 2019 Jul; 129(10):4492-4505. PubMed ID: 31361600
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation induces phenotypic plasticity and promotes resistance to molecular targeted therapy in a PTEN-deficient mouse model of prostate cancer.
De Velasco MA; Tanaka M; Yamamoto Y; Hatanaka Y; Koike H; Nishio K; Yoshikawa K; Uemura H
Carcinogenesis; 2014 Sep; 35(9):2142-53. PubMed ID: 24986896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
